share_log

Wedbush Reiterates Outperform on Elevation Oncology, Maintains $5 Price Target

Benzinga ·  Nov 6, 2023 10:20

Wedbush analyst Robert Driscoll reiterates Elevation Oncology (NASDAQ:ELEV) with a Outperform and maintains $5 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment